While cardiovascular outcomes were not a focus of the studies included in this meta-analysis, based on the results of cardiovascular outcome trials of empagliflozin, canagliflozin and dapagliflozin, SGLT2 inhibitor and metformin combination therapy potentially also has cardiac benefits among patients with established cardiovascular disease or multiple cardiovascular risk factors [8,9,10,11]. This evidence concerns the gene SLC5A2 and cardiovascular disorder.